Present evidence suggests, in addition to activation of the classical AR target genes, constitutively active AR splice variants are associated with a distinct transcription program in prostate cancer cells as well as in prostate cancer xenografts displaying treatment-induced AR-Vs expression [22]. The gene discussed is AR; the disease is prostate cancer.